Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 monoclonal antibody plus chemotherapy versus apatinib plus chemotherapy in third-line or later advanced gastric cancer
ChiCTR2200055533Phase 2Recruiting
- Sponsor
- Shanghai Xuhui District Central Hospital
- Start
- Jan 2022
- Modality
- Small Molecules, Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PD-1 Monoclonal Antibody and Rivoceranib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Shanghai Xuhui District Central Hospital. Primary endpoint: progression-free survival. Started Jan 2022; status: recruiting.
02
Drugs
PD-1 Monoclonal AntibodyRivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200055533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055533.